Cogent Biosciences (COGT) reported Monday its Q2 loss widened to $96.4 million from a loss of $73.5 million a year earlier.

Analysts polled by FactSet expected a loss of $98 million.

As of June 30, the company said it had $792.3 million in cash, cash equivalents and marketable securities and expected it could fund operations into late 2028.